Skip to main content
BrainCited

Ginkgo and Alzheimer's disease: little or no different from placebo.

Other Prescrire international 2007 2 citations
PubMed
<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'pmid\u003D17926840'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Study Type
Review
Population
None
Duration
25.799999999999997 weeks
Intervention
Ginkgo and Alzheimer's disease: little or no different from placebo. None
Comparator
None
Primary Outcome
Ginkgo and Alzheimer's disease: little or no different from placebo.
Effect Direction
Negative
Risk of Bias
Unclear

Abstract

(1) Drug treatments for Alzheimer's disease have no more than modest and transient efficacy but can cause significant adverse effects. Other treatments are therefore being explored, including plant extracts. (2) Is Ginkgo biloba (maidenhair tree) any more effective than placebo in Alzheimer's disease? To answer this question, we carried out a review of available evidence based on Prescrire's standard methodology. (3) Ginkgo biloba has been widely used for many years by people with symptoms attributed to "cerebrovascular insufficiency", despite the lack of evidence of a causal role. (4) About thirty placebo-controlled trials in patients with various types of dementia have been published, with highly inconsistent results. If these studies showed any effect on cognition, it was weak and did not last more than 6 months. (5) Cases of haemorrhage were reported, and this means that caution is needed, especially in patients at increased risk of haemorrhage, such as those on ongoing anticoagulant or antiplatelet treatment. (6) In practice, Ginkgo biloba extract appears to be little or no different from placebo in the treatment of Alzheimer's disease. Its short-term use is acceptable under some conditions, but the potential risk of bleeding must be kept in mind.

TL;DR

Ginkgo biloba extract appears to be little or no different from placebo in the treatment of Alzheimer's disease, and its short-term use is acceptable under some conditions, but the potential risk of bleeding must be kept in mind.

Used In Evidence Reviews

Similar Papers